10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Addi...
September 16 2019 - 4:10PM
10x Genomics (Nasdaq: TXG) today announced the closing of its
initial public offering of 11,500,000 shares of its Class A common
stock, which includes the exercise in full of the underwriters’
option to purchase 1,500,000 additional shares of its Class A
common stock, at a public offering price of $39.00 per share.
Including the option exercise, the aggregate gross proceeds from
the offering were $448.5 million, before deducting underwriting
discounts and commissions and estimated offering expenses. All of
the shares were offered by 10x Genomics. The shares began trading
on The Nasdaq Global Select Market on September 12, 2019, under the
ticker symbol “TXG.”
J.P. Morgan LLC, Goldman Sachs & Co. LLC and BofA Merrill
Lynch acted as lead joint book-running managers for the
offering. Cowen acted as lead manager for the offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission, and became
effective on September 11, 2019. The offering was made only by
means of a prospectus. Copies of the final prospectus may be
obtained from: J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717, by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New
York 10282, by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; or BofA Merrill Lynch,
NC1-004-03-43; 200 North College Street, 3rd Floor, Charlotte,
North Carolina 28255-0001, Attention: Prospectus Department, or by
email at dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About 10x Genomics10x Genomics is a life
science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world including 93 of the
top global research institutions and 13 of the top 15 global
pharmaceutical companies, and have been cited in over 500 research
papers on discoveries ranging from oncology to immunology and
auto-immune diseases.
ContactsInvestors:investors@10xgenomics.com
Media:media@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2023 to Apr 2024